Literature DB >> 10625666

PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression.

P Oettgen1, E Finger, Z Sun, Y Akbarali, U Thamrongsak, J Boltax, F Grall, A Dube, A Weiss, L Brown, G Quinn, K Kas, G Endress, C Kunsch, T A Libermann.   

Abstract

Prostate cancer, the most frequent solid cancer in older men, is a leading cause of cancer deaths. Although proliferation and differentiation of normal prostate epithelia and the initial growth of prostate cancer cells are androgen-dependent, prostate cancers ultimately become androgen-independent and refractory to hormone therapy. The prostate-specific antigen (PSA) gene has been widely used as a diagnostic indicator for androgen-dependent and -independent prostate cancer. Androgen-induced and prostate epithelium-specific PSA expression is regulated by a proximal promoter and an upstream enhancer via several androgen receptor binding sites. However, little progress has been made in identifying androgen-independent regulatory elements involved in PSA gene regulation. We report the isolation of a novel, prostate epithelium-specific Ets transcription factor, PDEF (prostate-derived Ets factor), that among the Ets family uniquely prefers binding to a GGAT rather than a GGAA core. PDEF acts as an androgen-independent transcriptional activator of the PSA promoter. PDEF also directly interacts with the DNA binding domain of androgen receptor and enhances androgen-mediated activation of the PSA promoter. Our results, as well as the critical roles of other Ets factors in cellular differentiation and tumorigenesis, strongly suggest that PDEF is an important regulator of prostate gland and/or prostate cancer development.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10625666     DOI: 10.1074/jbc.275.2.1216

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  84 in total

1.  Identification and confirmation of a module of coexpressed genes.

Authors:  H Garrett R Thompson; Joseph W Harris; Barbara J Wold; Stephen R Quake; James P Brody
Journal:  Genome Res       Date:  2002-10       Impact factor: 9.043

2.  Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.

Authors:  Makoto Sato; Mai Johnson; Liqun Zhang; Baohui Zhang; Kim Le; Sanjiv S Gambhir; Michael Carey; Lily Wu
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

Review 3.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

4.  Thrombocytopenia in mice lacking the carboxy-terminal regulatory domain of the Ets transcription factor Fli1.

Authors:  Omar Moussa; Amanda C LaRue; Romeo S Abangan; Christopher R Williams; Xian K Zhang; Masahiro Masuya; Yong Z Gong; Demetri D Spyropoulos; Makio Ogawa; Gary Gilkeson; Dennis K Watson
Journal:  Mol Cell Biol       Date:  2010-09-07       Impact factor: 4.272

5.  Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors.

Authors:  Peter C Hollenhorst; David A Jones; Barbara J Graves
Journal:  Nucleic Acids Res       Date:  2004-10-21       Impact factor: 16.971

6.  A major site of expression of the ets transcription factor Elf5 is epithelia of exocrine glands.

Authors:  Erika J Lapinskas; Jodie Palmer; Sharon Ricardo; Paul J Hertzog; Annet Hammacher; Melanie A Pritchard
Journal:  Histochem Cell Biol       Date:  2004-11-03       Impact factor: 4.304

Review 7.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

8.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

9.  A comprehensive catalogue of somatic mutations from a human cancer genome.

Authors:  Erin D Pleasance; R Keira Cheetham; Philip J Stephens; David J McBride; Sean J Humphray; Chris D Greenman; Ignacio Varela; Meng-Lay Lin; Gonzalo R Ordóñez; Graham R Bignell; Kai Ye; Julie Alipaz; Markus J Bauer; David Beare; Adam Butler; Richard J Carter; Lina Chen; Anthony J Cox; Sarah Edkins; Paula I Kokko-Gonzales; Niall A Gormley; Russell J Grocock; Christian D Haudenschild; Matthew M Hims; Terena James; Mingming Jia; Zoya Kingsbury; Catherine Leroy; John Marshall; Andrew Menzies; Laura J Mudie; Zemin Ning; Tom Royce; Ole B Schulz-Trieglaff; Anastassia Spiridou; Lucy A Stebbings; Lukasz Szajkowski; Jon Teague; David Williamson; Lynda Chin; Mark T Ross; Peter J Campbell; David R Bentley; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2009-12-16       Impact factor: 49.962

10.  PDEF is a negative regulator of colon cancer cell growth and migration.

Authors:  Omar Moussa; David P Turner; Ron J Feldman; Victor I Sementchenko; Brent D McCarragher; Mohamed M Desouki; Mostafa Fraig; Dennis K Watson
Journal:  J Cell Biochem       Date:  2009-12-15       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.